BIOENSIS 3D Antibody-Dependant Cellular Phagocytosis (ADCP) allows for better decision-making earlier in the drug development process. Our unique antibody-dependent cellular phagocytosis (ADCP) platforms enable efficacy evaluation of your therapeutic antibodies.
Key assay features:
• Over 150 target tumor cell lines available for testing
• Effector cells: human monocyte-derived macrophages
• Models tested high-throughput format
• Precision EC50 results
• Flexible testing protocols including single and combination agents
Please contact us to discuss your study and an up to date list of available cell lines
info@bioensis.com
